Executive Summary
Omega-3 products differ in molecule, dose, purity, absorption and regulatory quality. “Fish oil” is not one standardized intervention.
REDUCE-IT randomized 8,179 statin-treated high-risk patients with triglycerides 135-499 mg/dL to icosapent ethyl 4 g/day or mineral-oil placebo. The primary composite cardiovascular endpoint was reduced by 25% relative.
STRENGTH randomized more than 13,000 high-risk patients to a 4 g/day EPA+DHA carboxylic-acid formulation or corn-oil placebo and found no reduction in major cardiovascular events.
VITAL, a primary-prevention trial using 1 g/day marine omega-3, did not significantly reduce its primary major-cardiovascular-event endpoint overall.
The reason REDUCE-IT and STRENGTH diverged remains debated: EPA-only versus EPA+DHA, achieved EPA levels, formulation, placebo effects and mechanisms beyond triglyceride lowering are all candidates.
Both high-dose omega-3 strategies raise concern for atrial fibrillation. REDUCE-IT also showed more serious bleeding numerically, although absolute risks were modest.
The 2026 ACC/AHA guideline states that in adults age ≥50 with ASCVD or diabetes plus another risk factor, persistent TG 150-499 mg/dL and LDL-C <100 mg/dL on maximally tolerated statin, addition of icosapent ethyl may be reasonable to lower ASCVD risk.
Do not substitute generic fish oil for a prescription formulation when the clinical goal is replicating REDUCE-IT.
Figure 1. Prescription EPA, mixed EPA+DHA products and OTC supplements have different evidence bases and should not share the same outcome claim.
1. REDUCE-IT: what was proven
The trial population was not healthy people taking a wellness supplement. Participants were already on statin therapy and had established ASCVD or diabetes plus additional risk, with persistent triglyceride elevation.
The intervention was purified prescription icosapent ethyl at 4 g/day.
2. STRENGTH: why it matters
STRENGTH also used a high dose and a high-risk population, but the formulation contained both EPA and DHA and did not reduce cardiovascular events.
That makes “omega-3 lowers triglycerides” an insufficient explanation for REDUCE-IT.
3. What about OTC fish oil?
OTC products vary widely in EPA/DHA content and purity. Typical supplement doses are also much lower than 4 g/day prescription therapy.
Most importantly, the clinical outcomes trials do not allow the REDUCE-IT result to be transferred to every fish-oil capsule.
4. Risks
High-dose omega-3 therapy is associated with a small increase in atrial-fibrillation risk in several trials/meta-analyses. Bleeding risk also deserves review in patients taking antithrombotic therapy or with a bleeding disorder.
This is why prescription use should be tied to a population with expected net benefit — not taken as a general-purpose supplement.
| Intervention | Trial | Population | CV outcome |
|---|---|---|---|
| Icosapent ethyl 4 g/day (EPA-only) | REDUCE-IT | Statin-treated high-risk, TG 135-499 | Positive: 25% relative reduction in primary composite |
| EPA+DHA 4 g/day | STRENGTH | High-risk, atherogenic dyslipidemia | Neutral |
| Marine omega-3 1 g/day | VITAL | General primary prevention | Neutral for primary major CVD endpoint overall |
| Typical OTC fish oil | No single equivalent trial | Variable | Cannot inherit REDUCE-IT claim |
5. FAQ
Is Vascepa just expensive fish oil?
No. It is a regulated prescription EPA-only drug with a specific high-dose evidence base.
Does DHA raise LDL-C?
DHA-containing preparations can raise LDL-C in some hypertriglyceridemic patients; the effect varies by formulation and baseline metabolism.
Can I take OTC EPA instead?
You cannot assume dose, purity, bioavailability or outcomes equivalence.
Does eating fish help?
Fish can be part of a Mediterranean-style dietary pattern, but food-based recommendations are different from prescribing icosapent ethyl.
References
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
2. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events: STRENGTH. JAMA. 2020;324:2268-2280.
3. Manson JE, Cook NR, Lee IM, et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019.
4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia.